CEO David Ricks said last quarter's 45% growth in Lilly's revenue for its Mounjaro diabetes treatment, Zepbound obesity injections and other products in the incretin market wasn’t as big as expected.
Drops for Lilly and Big Tech weigh on Wall Street, even as most stocks rise
→
Ricks said that it will take time for insurers and the pharmacy system to implement its price cuts, so the drugmaker will immediately cap monthly out-of-pocket costs at $35 for people who are not covered by Medicare’s prescription drug program.
Eli Lilly plans to slash some insulin prices, expand cost cap
→
